NEUROBO PHARMACEUTICALS INC (NRBO)       1.42  -0.1 (-6.58%)

1.42  -0.1 (-6.58%)

US64132R2067 - Common Stock - Premarket: 1.45 +0.03 (+2.11%)

NEUROBO PHARMACEUTICALS INC1.42

NASDAQ:NRBO (12/6/2022, 7:00:01 PM)-0.1 (-6.58%)

Premarket: 1.45 +0.03 (+2.11%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-14 2022-11-14/bmo Earnings (Next) 03-30 2023-03-30
Ins Owners 2.83% Inst Owners 0.01%
Market Cap 9.24M Shares 6.50M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 82.86
IPO 08-05 2016-08-05

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

NRBO Daily chart

Company Profile

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. The company is headquartered in Boston, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2016-08-05. The firm is engaged in providing therapeutic programs designed to impact a range of indications in coronavirus, neurodegenerative and cardiometabolic disease. Its products include ANA001, Niclosamide, NB-01 and NB-02. The ANA001 is an oral niclosamide formulation and is being developed as a treatment for patients with moderate coronavirus disease. Niclosamide is a potential oral antiviral and anti-inflammatory agent and being studied in a 60-subject Phase II clinical trial conducted in the United States. NB-01 primarily focused on the development of a treatment for painful diabetic neuropathy (PDN). NB-02 has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of a protein called tau, and with amyloid beta plaque deposition.

Company Info

NEUROBO PHARMACEUTICALS INC

200 Berkeley St., Fl 19

Boston MASSACHUSETTS 02116

P: 18577029600.0

CEO: Richard Kang

Employees: 5

Website: https://www.neurobopharma.com/

NRBO News

News Image21 days ago - IssueWireThe Center for Advancing Innovation's Board Member, Gil Price, Realizes Turn Around in Less than 12 Months

The Center for Advancing Innovation’s Board Member, Gil Price, Realizes Turn Around in Less than 12 Months - IssueWire

News Imagea month ago - FinancialNewsMediaBiotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MACK),(NASDAQ:NRBO),(NYSE:MRK),(NASDAQ:RNAZ), EQNX::TICKER_END

News Imagea month ago - FinancialNewsMedia.comBiotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - The pancreatic cancer treatment market is fiercely competitive. To maintain the escalating market...

News Imagea month ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start the day with an overview of the biggest pre-market stock movers traders need to know about for Thursday!

News Imagea month ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday!

NRBO Twits

Here you can normally see the latest stock twits on NRBO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example